Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CyberdyneTSE:7779 +1.33%72 Debt-to-EBITDA is 0.30 as of Mar. 2026, which is 61% below its 10-year median of 0.77. GuruFocus rates TSE:7779 with a GF Score™ of 72/100 and a GF Value™ of 円212.04 (Fairly Valued). The stock has 2 warning signs investors should review. Among 471 Medical Devices & Instruments companies, Cyberdyne ranks better than 78.77% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Cyberdyne's Debt-to-EBITDA or its related term are showing as below:
TSE:7779'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.32 Med: 0.77 Max: 35.11
Current: 0.32
During the past 13 years, the highest Debt-to-EBITDA Ratio of Cyberdyne was 35.11. The lowest was 0.32. And the median was 0.77.
TSE:7779's Debt-to-EBITDA is ranked better than 78.77% of 471
companies
in the Medical Devices & Instruments industry
Industry Median: 1.64
vs TSE:7779: 0.32
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Cyberdyne Debt-to-EBITDA Related Terms
Cyberdyne Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Cyberdyne's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:7779 vs ABT, SYK, MDT: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, Cyberdyne's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cyberdyne Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cyberdyne's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Cyberdyne's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Cyberdyne (TSE:7779) has a Debt-to-EBITDA of 0.30 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Cyberdyne. This is 61% below median its historical median of 0.77. Over the past decade, Cyberdyne's Debt-to-EBITDA has ranged from 0.32 to 35.11. According to the industry distribution chart, Cyberdyne ranks #100 out of 471 companies in the Medical Devices & Instruments industry, placing it in the top 21.2%.
Is Cyberdyne's Debt-to-EBITDA too high?
Cyberdyne's current Debt-to-EBITDA of 0.30 is 61% below median its 10-year median of 0.77. Over the past 10 years, this metric has ranged from a low of 0.32 to a high of 35.11. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.64. Cyberdyne's value of 0.30 is 81.7% below this industry median. Based on the distribution chart, Cyberdyne ranks #100 out of 471 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Cyberdyne has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cyberdyne's Debt-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Cyberdyne ranks #100 out of 471 companies for Debt-to-EBITDA. This places Cyberdyne in the top 21% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 1.64. Cyberdyne's value of 0.30 is 81.7% below this benchmark. Historically, Cyberdyne's own Debt-to-EBITDA has ranged from 0.32 to 35.11 over the past decade. While the company's 10-year median is 0.77 vs. the industry median of 1.64, Cyberdyne has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.64, based on 471 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cyberdyne's current Debt-to-EBITDA of 0.30 is 81.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Cyberdyne. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cyberdyne's current Debt-to-EBITDA is 0.30, which is 61% below median its own 10-year median of 0.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyberdyne stock overvalued right now?
Based on GuruFocus' analysis, Cyberdyne (TSE:7779) is currently considered Fairly Valued. The stock's GF Value™ is 円212.04, compared to a current price of 円229.00 — trading 8% above its estimated fair value. The current Debt-to-EBITDA is 0.30, which is 61% below median its 10-year median of 0.77 and 81.7% below the Medical Devices & Instruments industry median of 1.64. Cyberdyne's overall GF Score™ is 72/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Cyberdyne (TSE:7779), the current Debt-to-EBITDA is 0.30 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cyberdyne (TSE:7779) Overvalued in 2026?
Based on GuruFocus' analysis, Cyberdyne stock appears to be overvalued.
The current stock price of 円229.00 is trading 8% above its estimated GF Value™ of 円212.04.
GuruFocus considers Cyberdyne to be Fairly Valued.
Key valuation signals for TSE:7779:
Debt-to-EBITDA: 0.30 (61% below median its 10-year median of 0.77)
GF Value™: 円212.04 vs. price of 円229.00 (8% above fair value)
Industry Position: 81.7% below the Medical Devices & Instruments median (#100 of 471)
No single metric tells the full story. See the TSE:7779 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cyberdyne Inc is a Japanese based company engaged in the research and development of medical welfare equipment and systems. It offers equipment and systems for rehabilitation support, body function support for elderly and disabled people, rescue support in disaster sites, entertainments, and heavy labor support in factories. Its products include Hybrid Assistive Limb (HAL) for the lower limb, single joint, lumbar, Table Interface and Cleaning Robots. In addition, it also offers services in respect to medical service and non-medical service which includes HAL therapy under medical service, and Hal fit and Robo care service under non-medical service.
72GF Score
Get the complete analysis for TSE:7779
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:7779 has been successfully added to your 
